Dermatology Times

10/10/2024

💡 EXPERT INSIGHTS: Melinda Gooderham, MSc, MD, FRCPC, shares pearls and key takeaways from new data on the treatment of psoriasis with zasocitinib. The data was presented at .

🎥 View the full interview now:

Melinda Gooderham, MSc, MD, FRCPC, emphasized the significance of the study’s results, showcasing stable laboratory parameters over a 12-week trial.

10/08/2024

📹CLINICAL CASE COLLECTIVE: Gain comprehensive insights into the evolving treatment landscape, nonsteroidal therapies, and current data trends. Delve into a detailed case study highlighting treatment selection and shared decision-making for better outcomes.
Stay informed on the latest in psoriasis care: https://ow.ly/o07350TGeRT

10/07/2024

🌟 EXPERT INSIGHTS: Jason Hawkes, MD, MS, provides insights into the key differences between atopic dermatitis and prurigo nodularis, including appearance, cytokine pathways associated with each condition, patient populations, biologic use, and more.

🖇 Read more:

Jason Hawkes, MD, MS, emphasized the importance of biologic treatments transforming the management of both prurigo nodularis and atopic dermatitis.

10/07/2024

🚨 BREAKING NEWS: A second study has confirmed initial reports of presence and formulation in acne products—this time, with testing conducted at room temperature.

Results demonstrated that 34% of 111 tested products, equivalent to 38 products, contained benzene levels above the FDA's 2 parts per million limit.

"For colleagues with questions or concerns, I encourage them first to read carefully the primary research articles. Then, the single most immediate step they could take to mitigate concerns about using benzoyl peroxide products or patient fears is to encourage refrigeration of the medicine at all times, replace the medicine every ~ 12 weeks, and avoid storage in or near heat and sunlight," Christopher Bunick, MD, PhD, told Dermatology Times.

New peer-reviewed research published in the Journal of Investigative Dermatology examined 111 products at room temperature.

10/06/2024

📹 CASE-BASED PEER PERSPECTIVE: How is plaque psoriasis treatment evolving? E. James Song, MD, FAAD, explores the latest advancements in therapy.

Watch the series now: https://ow.ly/abse50TBnbo

10/06/2024

🌟 Today is , which kicks off National PA Week, October 6-12. PAs are integral to dermatology, providing high-quality patient management and enhancing access to care.

Join us in celebrating the dedication and expertise of PAs who play a vital role in improving skin health outcomes.

https://www.dermatologytimes.com/clinical/np-pa

10/05/2024

🌟📰 Our October issue is accompanied by 2 print supplements centered around challenging cases of acne and vitiligo.

They feature practical insights from Hilary Baldwin, MD; James Del Rosso, DO; Heather Woolery-Lloyd, MD; Andrew Alexis, MD, MPH; Chesahna Kindred, MD; Ted Lain, MD, MBA; and Pearl Grimes, MD.

Download now and follow along as we share more throughout the month. ⬇️

https://www.dermatologytimes.com/journals/dermatology-times

10/05/2024

🌟📰 The October issue of Dermatology Times is live! This month, we delve into non-surgical approaches to squamous cell carcinoma in older patients, changing perceptions of medical aesthetics, and more.

Download now and follow along as we share more throughout the month. ⬇️

https://www.dermatologytimes.com/journals/dermatology-times

10/05/2024

Explore this informative Partner Perspective to gain a deeper understanding of chronic spontaneous urticaria. Learn more about its clinical features and its impact on patients.
Start the series here: https://ow.ly/xVSf50TEB23

10/04/2024

🌟 EXPERT INSIGHTS: Arcutis Biotherapeutics recently released promising new data from its phase 3 clinical trials, INTEGUMENT-1 and INTEGUMENT-2.

🎥 Watch the full interview now:

After releasing promising data from several clinical trials, Burnett discussed the importance of studying efficacy and safety across diverse populations.

10/02/2024

📹 DERMVIEW: Learn about the challenges of managing pediatric plaque psoriasis with Karan Lal, DO, and Helen T. Shin, MD.

Watch here: https://ow.ly/HKHm50TBetU

10/02/2024

🌟 EXPERT INSIGHTS: Melinda Gooderham, MSc, MD, FRCPC, details the results of the ADjoin long-term extension trial evaluating the 3-year safety and efficacy data of lebrikizumab in .

🎥 Watch the full interview now:

Gooderham reviews key highlights from EADV 2024 on the ADjoin long-term extension trial for patients with moderate to severe AD.

10/01/2024

🌟 October 1-7 is Body-Focused Repetitive Behaviors (BFRB) Awareness Week, and we're raising awareness about the impact of BFRBs, such as trichotillomania and dermatillomania, on dermatological health.

These conditions are often underrecognized but can cause significant skin damage, infections, and scarring. Early diagnosis and multidisciplinary treatment are crucial for patient care.

10/01/2024

🌟 October is National .

This month, let’s focus on early diagnosis, personalized treatment plans, and patient education. Together, we can improve outcomes for millions affected by this condition.

https://www.dermatologytimes.com/clinical/eczema

09/30/2024

🌟 EXPERT INSIGHTS: Kilian Eyerich, MD, PhD, shares insights into the significance of the Measure Up 1 and Measure Up 2 phase 3 studies and their evaluation of for the treatment of patients with in the head and neck regions.

🖇 Read more:

Kilian Eyerich, MD, PhD, shares insights into an EADV 2024 presentation on upadacitinib’s ability to achieve almost total skin clearance in the head and neck regions with minimal effect on quality of life.

09/30/2024

📰 The September issue of Dermatology Times features botulinum toxin. This edition includes comprehensive articles and insights from leading dermatologists, helping you stay informed about the latest developments in the field. Gain valuable knowledge that can improve your practice and patient care.

Subscribe Now: https://ow.ly/Ikuq50TvzVA

09/28/2024

Through collaboration with Nimbus Therapeutics and Schrodinger, zasocitinib’s AI-driven design maximizes its fit within the targeted enzyme.

09/27/2024

📹 BETWEEN THE LINES: Curious about why health care providers switch treatments for atopic dermatitis?
This series delves into real-world insights and expert experiences. Stay informed on the nuances of AD management and patient care.
Watch Here: https://ow.ly/rMfx50Txoki

09/27/2024

🌟 EXPERT INSIGHTS: Christopher Bunick, MD, PhD, discusses what he calls a “next-generation TYK2 inhibitor,” , highlighting its high selectivity and potency and spotlighting data from clinical trials shared at the European Society for Dermatological Research.

🎥 View the full interview now:

Christopher Bunick, MD, PhD, shared insights into zasocitinib’s presented data and ongoing clinical trials.

09/26/2024

🌟 EXPERT INSIGHTS: Aaron Farberg, MD, shares insights into a recent retrospective cohort study highlighting the effectiveness of image-guided superficial radiation Therapy for treating non melanoma skin cancer.

🎥 View the full interview now:

Farberg discusses data recently published in Geriatrics demonstrating low rates of recurrence.

09/26/2024

🌟 EXPERT INSIGHTS: Iain Stuart, PhD, discusses the outcomes of VYNE Therapeutics' recent phase 1a trial for VYN202, details of the upcoming multiple ascending dose trial, and the potential of BET inhibition in immuno-inflammatory conditions.

🎥 Watch the full interview now:

VYNE recently announced positive results for its novel oral small molecule BD2-selective BET inhibitor in a single-ascending dose clinical trial.

09/25/2024

🌟 This week, Dermatology Times is celebrating — a time aimed at celebrating and empowering our network of advanced practice providers.

But even when the week is over, you can still count on us to uplift nurse practitioner and physician assistant voices.

https://www.dermatologytimes.com/clinical/np-pa

09/25/2024

📹FRONTLINE FORUM: Navigate the complexities of atopic dermatitis with expert insights as Linda Stein Gold, MD, and Michael Cameron, MD, FAAD, review the rapid itch relief provided by topical ruxolitinib cream, attributing its fast-acting efficacy to its mechanism of action targeting multiple interleukins. Watch here: https://ow.ly/fgfF50TuLbF

09/23/2024

🚨 NEW TODAY: The US FDA has approved UCB's bimekizumab-bkzx (Bimzelx) for adult patients with active psoriatic arthritis.

The drug also received approvals for adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation and adults with active ankylosing spondylitis.

🖇 Read more:

Bimzelx was also approved for non-radiographic axial spondyloarthritis and ankylosing spondylitis.

09/22/2024

🌟 EXPERT INSIGHTS: Elyse Love, MD, shares insights into AbbVie's 2024-2025 Immunology Scholarship, including its impacts for individuals with chronic skin conditions who are also striving for academic success.

"The AbbVie Immunology Scholarship eases financial pressure faced by students living with chronic disease by covering tuition and educational expenses, which allows students to focus on their academic goals rather than the costs of higher education," Love said.

🖇 Read more:

Elyse Love, MD, discusses the role of the program in supporting students with skin conditions the financial support and empowerment necessary for academic success.